Last reviewed · How we verify

NCT05397314

DNA Fragmentation - Effect on Pregnancy Rate

Completed NA Last updated 31 May 2022
What this trial tests

NA trial testing Punalpin in Infertility, Male in 40 participants. Completed in 9 April 2021.

Timeline
1 January 2016
Primary endpoint
9 January 2021
9 April 2021

Quick facts

Lead sponsorOdense University Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingdouble
Primary purposetreatment
Enrollment40
Start date1 January 2016
Primary completion9 January 2021
Estimated completion9 April 2021

Drugs / interventions tested

Conditions studied

Sponsor

Odense University Hospital

Who can join

18 and older, any sex, with Infertility, Male. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether Punalpin, an antioxidant, has a positive impact on DNA fragmentation in spermatozoa in male fertility patients with increased amount of DNA fragmentation in their spermatozoa. Secondary purpose is to investigate whether there is any positive effect on the subsequent pregnancy rates from the fertility treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Infertility, Male

Currently open trials in the same condition.

Other Odense University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05397314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing